Otsuka enters the API business after Astellas asset acquisition

By Ben Hargreaves contact

- Last updated on GMT

Otsuka Chemical enters the API business

Related tags: Astellas, Otsuka Chemical, Cefixime, Antibiotics

Otsuka acquires Astellas’ Cefixime business, which means it will supply the API to overseas licensees and thereby enter the API business.

Otsuka Chemical will acquire the Cefixime business from fellow Japanese firm, Astellas Pharma, which allows the former company to build on its existing antibiotic intermediates business with the addition of antibiotic active pharmaceutical ingredients (APIs).

Cefixime was developed by Astellas and is a third-generation cephalosporin antibiotic that is active against gram-positive and gram-negative bacteria. It is used to treat various conditions, including ear infections, tonsillitis, and pneumonia.

The acquisition sees Otsuka gain the rights to supply the API to overseas licensees, as well as picking up contracts belonging to the licensing business and the trademark.

Moving forward, Otsuka stated that it will strengthen the “manufacturing technology of high-quality API and their marketing and brand power to promote pharmaceutical-related business.”

The divestiture for Astellas fits in with a shift in strategy that has seen the company prioritise its ophthalmology portfolio​, as well as reducing its activity in the area of antibody-drug conjugates​.

Financials of the acqusitions were not revealed.

Related news

Show more

Related products

Lactium, your ally to manage day to day stress

Lactium, your ally to manage day to day stress

Ingredia | 27-Aug-2020 | Product Presentation

Stress has been called the ‘health epidemic of the 21st century’ by the World Health Organization. Increasingly, consumers are looking for safe, reliable...

Follow us


View more